The latest installment in BioPharma Dive’s visualization-focused series looks at Wall Street’s response to a trio of closely ...

Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood ...

The San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or ...

Etiome, Cellarity and Empress Therapeutics are being combined into one new AI-aided drugmaker claiming to possess the ability ...

RFK Jr. has given notice that the agency won’t take enforcement action on six peptides that controversially won a contested ...

The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher ...

The buyout hands Ferring rights to a technology capable of simplifying the lengthy and burdensome process of in vitro ...

The plan builds on recent FDA moves to speed "personalized" treatments by offering an approval framework for therapies ...

Lilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on ...

At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share ...